Pirfenidone
Pirfenidon Cipla contains the active substance pirfenidone and is used to treat idiopathic pulmonary fibrosis in adults.
Idiopathic pulmonary fibrosis is a condition in which the tissue in the lungs becomes swollen and scarred over time, leading to difficulty breathing deeply. This makes it hard for the lungs to work properly. Pirfenidon Cipla helps reduce scarring and swelling in the lungs and helps improve breathing.
If any of the above conditions apply to you, do not take Pirfenidon Cipla.
In case of doubt, consult your doctor or pharmacist.
Before starting treatment with Pirfenidon Cipla, discuss it with your doctor or pharmacist.
Pirfenidon Cipla may cause severe liver damage, and some cases have been fatal. Before starting treatment with Pirfenidon Cipla, blood tests will be performed, which will be repeated every month for the first 6 months of treatment, and then every 3 months for the entire duration of treatment to monitor liver function. It is essential to perform regular blood tests throughout the treatment with Pirfenidon Cipla.
Pirfenidon Cipla should not be given to children and adolescents under 18 years of age.
Tell your doctor or pharmacist about all medicines you are taking, have recently taken, or might take.
This is especially important if you are taking any of the following medicines, as they may affect the way Pirfenidon Cipla works:
Medicines that may reduce the effect of Pirfenidon Cipla:
Do not drink grapefruit juice while taking this medicine. Grapefruit may interfere with the proper functioning of Pirfenidon Cipla.
As a precautionary measure, it is better to avoid taking Pirfenidon Cipla if you are pregnant, plan to become pregnant, or think you may be pregnant, as the potential risk to the unborn child is unknown.
If you are breast-feeding or plan to breast-feed, consult your doctor or pharmacist before taking Pirfenidon Cipla. It is not known whether Pirfenidon Cipla passes into human milk, so your doctor will discuss the risks and benefits of taking this medicine while breast-feeding, if you decide to breast-feed during treatment.
Do not drive or operate any machinery if you experience dizziness or fatigue after taking Pirfenidon Cipla.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, which is essentially 'sodium-free'.
Treatment with Pirfenidon Cipla should be started and supervised by a specialist doctor with experience in the diagnosis and treatment of idiopathic pulmonary fibrosis.
Always take this medicine exactly as your doctor or pharmacist has told you. If you are not sure, ask your doctor or pharmacist.
The medicine is usually taken in increasing doses as follows:
The recommended maintenance dose of Pirfenidon Cipla is 801 mg (3 yellow tablets or 1 pink tablet) 3 times a day with food, which is a total of 2403 mg/day.
Swallow the tablets whole with water, during or after meals to reduce the risk of side effects such as nausea (vomiting) and dizziness. If symptoms persist, consult your doctor.
Your doctor may reduce the dose of Pirfenidon Cipla if you experience side effects such as stomach problems, any skin reactions to sunlight or sunlamps, or significant changes in liver enzyme activity.
If you have taken more tablets than recommended, contact your doctor, pharmacist, or the nearest hospital emergency department immediately and take the medicine with you.
If you miss a dose, take it as soon as you remember. Do not take a double dose to make up for a missed dose. Maintain at least a 3-hour interval between doses. Do not take more tablets in a day than the recommended daily dose.
In certain situations, your doctor may advise you to stop taking Pirfenidon Cipla. If it is necessary to stop taking this medicine for a period of more than 14 consecutive days, your doctor will restart treatment with a dose of 267 mg 3 times a day, gradually increasing the dose to 801 mg 3 times a day.
If you have any further questions about taking this medicine, ask your doctor or pharmacist.
Like all medicines, Pirfenidon Cipla can cause side effects, although not everybody gets them.
Stop taking Pirfenidon Cipla and seek medical attention immediately if you experience any of the following symptoms:
Talk to your doctor if you experience any side effects.
Very Common Side Effects(may affect more than 1 in 10 people):
Common Side Effects(may affect up to 1 in 10 people):
Uncommon Side Effects(may affect up to 1 in 100 people):
If you experience any side effects, talk to your doctor or pharmacist. You can also report side effects directly to the
Department of Drug Safety Monitoring of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181C
PL-02 222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
You can also report side effects to the marketing authorization holder.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month.
There are no special storage instructions for this medicine.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
267 mg Tablet
Pirfenidon Cipla, 267 mg, film-coated tablets are yellow to light yellow, biconvex, oval, with beveled edges, smooth on both sides. The dimensions of the tablet are approximately 14 mm x 7 mm.
Starting treatment pack for 2 weeks: a multipack containing 63 film-coated tablets (consisting of 1 pack of 21 film-coated tablets and 1 pack of 42 film-coated tablets).
84 film-coated tablets.
Maintenance treatment pack: a multipack containing 252 film-coated tablets (3 packs, each containing 84 film-coated tablets).
801 mg Tablet
Pirfenidon Cipla, 801 mg, film-coated tablets are pink to light pink, biconvex, capsule-shaped, smooth on both sides. The dimensions of the tablet are approximately 20 mm x 9 mm.
84 film-coated tablets.
Maintenance treatment pack: a multipack containing 252 film-coated tablets (3 packs, each containing 84 film-coated tablets).
The blisters are marked with the following symbols and abbreviations for the days of the week, which remind you to take a dose three times a day:
(sunrise, morning dose)
(sun, daytime dose) and
(moon, evening dose).
Mon. Tue. Wed. Thu. Fri. Sat. Sun.
Not all pack sizes may be marketed.
De Keyserlei 58-60,
Box-19, 2018
Antwerp
Belgium
tel: +32(0)32910101/ +32(0) 32910199
De Keyserlei 58-60, Box-19, 2018 Antwerp,
Belgium
Sweden | Pirfenidon Cipla |
Belgium | Pirfenidon Cipla |
Germany | Pirfenidon Cipla |
Spain | PIRFENIDONA CIPLA |
Norway | Pirfenidon Cipla |
France | PIRFENIDONE CIPLA |
Italy | Pirfenidone Cipla |
Poland | Pirfenidon Cipla |
Ireland | Pirfenidone Cipla |
Finland | Pirfenidon Cipla |
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.